<DOC>
	<DOCNO>NCT00994695</DOCNO>
	<brief_summary>Primary objective : To assess immunogenicity Mencevax ACW135 polysaccharide vaccine 28 day ( +6days ) post vaccination 2-4 , 5-14 , 15-29 year age group compare immunogenicity age group . Secondary Objectives : - To estimate incidence common adverse event follow immunization ( AEFI ) GSK Nm ACW135 polysaccharide vaccine 1h , 1d , 2d , 3d , 7d 28 day post-vaccination - To assess persistence antibody meningitis A , C W135 11 23 month post vaccination 2-4 , 5-14 , 15-29 year age group Study site : Two rural community ( Kebele ) Butajira district , Ethiopia . Methods : - Phase II , open parallel safety immunogenicity trial . - 234 young child ( 2-4 year ) , 145 old child ( 5-14 year ) 33 adult ( 15-29 year age ) randomly select demographic surveillance database enrol screen consenting . - Study participant receive Mencevax ACW polysaccharide vaccine 50 mg 0.5ml subcutaneously . - Blood sample measure SBA titre collect pre vaccination day 28 ( +6 day ) post vaccination . - Active follow AEFI post vaccination day 0 , 1 , 2 , 3 , 7 , &amp; 28 . - Primary end point vaccine response define sero-conversion ( subject initially seronegative ) 4 fold increase ( subject initially seropositive ) serum bactericidal antibody ( SBA ) serogroups Men A , C W135 ) post vaccination day 28 . In addition seroconversion assess ELISA Men A IgG day 0 day 28 post vaccination . - Secondary endpoint incidence general local symptom adverse event follow immunisation post vaccination period day 0 28 immune persistence post vaccination month-11 month-23 . Results : - No significant difference incidence general local AEFI observe age group - The statistical analysis Immunogenicity data progress</brief_summary>
	<brief_title>Safety , Immunogenicity Reactogenicity Trial Mencevax ACW135 Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Age 229 year , sex , live select village Butajira area 2 . A write informed consent sign individual ( &gt; =18y ) caretaker/guardian ( 2 17 year age ) 18 legal age maturity Ethiopia . Assent children/adolescents age 1217 year old . 3 . Free obvious health problem ascertain medical history clinical examination day enrolment 1 . Those unlikely complete follow 4weeks postvaccination . 2 . Use investigational nonregistered drug vaccine study vaccine within 30 day precede first dose study vaccine , plan use study period . 3 . Administration blood transfusion within 2 year prior enrolment plan use study period . 4 . Verbal report previous vaccination meningococcal serogroup A , C , Y W135 vaccine since 1999 . 5 . Confirmed suspected immunosuppressive immunodeficient condition include HIV infection . 6 . A family history congenital hereditary immunodeficiency . 7 . History allergic reaction component vaccine 8 . Presence fever ( defined axillary temperature 37.5 degree centigrade ) and/or severe illness day enrolment/ vaccination . 9 . Pregnancy . 10. lactation</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Trivalent meningococcal polysaccharide vaccine</keyword>
	<keyword>Children</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>To assess Safety trivalent meningococcal polysaccharide vaccine child</keyword>
	<keyword>To assess immunogenicity trivalent polysaccharide vaccine child</keyword>
</DOC>